Timothy C. Barabe, Director at Cartesian Therapeutics, Inc. (RNAC), bought 30,000 shares at $6.86 ($206K) on 2025-12-04, disclosed to the SEC on 2025-12-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| SELB | BUY | 2021-08-20 | $36K | — | Filing → |
| SELB | BUY | 2021-03-30 | $41K | — | Filing → |
| VEEV | SELL | 2020-10-15 | $798K | — | Filing → |